obesity

[Lipids in Health and Disease] Owing to antiviral, anti-inflammatory, immunomodulatory, and cardioprotective activity, statin therapy has been considered as valuable tool to improve COVID-19 outcomes.

[Seal Rock Therapeutics, Inc.] Seal Rock Therapeutics, Inc. announced completion of the single ascending dose portion of its Phase I clinical trial of SRT-015, a next-generation, liver-selective inhibitor of Apoptosis Signal-regulating Kinase 1 for non-alcoholic steatohepatitis (NASH) and other liver diseases such as alcoholic hepatitis.

[Nature Communications] In obesity, macrophages drive a low-grade systemic inflammation and insulin resistance. Scientists reported an unexpected location and function of NOC4L, which was preferentially expressed in human and mouse macrophages.

[Clinica Chimica Acta] Investigators discuss the current state of non-alcoholic fatty liver disease metabolites, gut micro-environmental changes, and the further challenges in digital metabolomics profiling.

[Leukemia] The authors provide a detailed summary of what is known about the impact of obesity on the pathogenesis of multiple myeloma (MM), its influence on outcomes in MM patients, and discuss potential mechanisms through which obesity is postulated to influence MM risk and prognosis.

[Acta Pharmacologica Sinica] The authors showed that interrupting TRPV4–Nox2 coupling by TRPV4 knockout, or by treatment with a specific Nox2 inhibitor Nox2 dstat or a specific TRPV4 inhibitor HC067046 significantly attenuated obesity-induced ROS overproduction in aortic endothelial cells, and reversed the abnormal endothelial cytoskeletal structure.